Company Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
109.3 USD +2.03% Intraday chart for Jazz Pharmaceuticals plc -3.72% -11.16%

Business Summary

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Number of employees: 2,800

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
3,659 100.0 % 3,834 100.0 % +4.78%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
91.0 %
3,370 92.1 % 3,490 91.0 % +3.55%
Europe
7.0 %
240 6.5 % 269 7.0 % +12.35%
All Other
2.0 %
49 1.3 % 75 2.0 % +51.92%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 03-02-28
President 52 20-03-15
Chief Tech/Sci/R&D Officer 57 19-05-28
Director/Board Member 63 12-01-17
Investor Relations Contact - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Human Resources Officer 53 18-10-31
General Counsel 49 19-06-30
Corporate Secretary - -

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 60 03-02-28
Director/Board Member 66 13-05-12
Director/Board Member 62 08-12-31
Director/Board Member 69 13-05-07
Director/Board Member 57 03-12-31
Director/Board Member 64 09-12-31
Director/Board Member 63 12-01-17
Director/Board Member 62 13-05-01
Director/Board Member 71 12-07-26
Director/Board Member 56 19-02-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,345,283 60,588,007 ( 97.18 %) 0 97.18 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.21 %
6,363,748 10.21 % 766 M $
BlackRock Advisors LLC
9.676 %
6,032,719 9.676 % 726 M $
2,421,125 3.883 % 292 M $
LSV Asset Management
3.758 %
2,343,227 3.758 % 282 M $
JPMorgan Investment Management, Inc.
2.235 %
1,393,659 2.235 % 168 M $
Ameriprise Financial Services LLC
2.106 %
1,312,771 2.106 % 158 M $
Wellington Management Co. LLP
2.053 %
1,280,197 2.053 % 154 M $
Polaris Capital Management LLC
2.033 %
1,267,460 2.033 % 153 M $
Renaissance Technologies LLC
1.975 %
1,231,574 1.975 % 148 M $
Fidelity Management & Research Co. LLC
1.969 %
1,227,827 1.969 % 148 M $
NameEquities%Valuation
ANIMA Sgr SpA
-
1,105 - 133 064 $

Company contact information

Jazz Pharmaceuticals Plc

Waterloo Exchange Waterloo Road

4, Dublin

+353 1 634 7800

http://www.jazzpharmaceuticals.com
address Jazz Pharmaceuticals plc(JAZZ)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Jazz Financing I DAC
Finance/Rental/Leasing
Jazz Securities DAC
Finance/Rental/Leasing
Jazz Investments II Ltd.
Finance/Rental/Leasing
Finance/Rental/Leasing
Jazz Investments Europe Ltd.
Jazz Pharmaceuticals Ireland Holdings Ltd.
Jazz Financing Holdings Ltd.

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
109.3 USD
Average target price
188.1 USD
Spread / Average Target
+72.15%
Consensus
  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Company Jazz Pharmaceuticals plc